

Jill P Buyon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4240450/publications.pdf>

Version: 2024-02-01

210
papers

20,735
citations

9264

74
h-index

10734

138
g-index

221
all docs

221
docs citations

221
times ranked

13348
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following <sc>SARS</sc>â€“<sc>CoV</sc>â€2 Vaccination. Arthritis and Rheumatology, 2022, 74, 284-294.	5.6	103
2	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology, 2022, 61, 4335-4343.	1.9	6
3	Urine Proteomics and Renal <sc>Singleâ€Cell</sc> Transcriptomics Implicate Interleukinâ€16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	5.6	38
4	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
5	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. Journal of Rheumatology, 2022, 49, 388-397.	2.0	11
6	Gut dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus. Gut Microbes, 2022, 14, .	9.8	6
7	Reducing the burden of surveillance in pregnant womenâ€with no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers. American Journal of Obstetrics and Gynecology, 2022, 227, 761.e1-761.e10.	1.3	4
8	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatology, The, 2022, 4, e582-e585.	3.9	9
9	Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment. , 2021, , 507-519.		1
10	Passively acquired lupus in the fetus and neonate. , 2021, , 325-363.		0
11	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000475.	2.7	10
12	Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. Journal of Experimental Medicine, 2021, 218, .	8.5	61
13	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
14	Microvascular endothelial glycocalyx thickness is associated with brachial artery flow-mediated dilation. Vascular Medicine, 2021, 26, 563-565.	1.5	2
15	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. Lancet Rheumatology, The, 2021, 3, e585-e594.	3.9	18
16	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	2.7	5
17	Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. Life Science Alliance, 2021, 4, e202101180.	2.8	15
18	511â€...Disease flares in lupus are concordant with <i>Ruminococcus Blautia Gnavus</i> blooms arising within unstable gut microbiota communities. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	1206â€¦Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus. , 2021, , .		2
20	901â€¦Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. , 2021, , .		0
21	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
22	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
23	Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block. Cardiovascular Research, 2020, 116, 1446-1457.	3.8	80
24	Autoimmune-mediated congenital heart block. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 64, 41-51.	2.8	38
25	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care and Research, 2020, 72, 233-242.	3.4	17
26	Factors associated with long-term cardiac dysfunction in neonatal lupus. Annals of the Rheumatic Diseases, 2020, 79, 217-224.	0.9	6
27	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology, 2020, 76, 292-302.	2.8	97
28	Breast feeding in the systemic lupus erythematosus patient. Lupus, 2020, 29, 1314-1315.	1.6	0
29	Leveraging the United States Epicenter to Provide Insights on COVIDâ€™19 in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1971-1980.	5.6	51
30	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008686.	4.8	16
31	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. Arthritis Research and Therapy, 2020, 22, 191.	3.5	21
32	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nature Communications, 2020, 11, 2197.	12.8	55
33	598: The effect of maternal autoimmune disease on fetal thymus size in the mid-trimester. American Journal of Obstetrics and Gynecology, 2020, 222, S384.	1.3	0
34	Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Research and Therapy, 2020, 22, 52.	3.5	37
35	Thoughts on COVID-19 and autoimmune diseases. Lupus Science and Medicine, 2020, 7, e000396.	2.7	31
36	Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science and Medicine, 2020, 7, e000377.	2.7	7

#	ARTICLE	IF	CITATIONS
37	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis and Rheumatology, 2020, 72, 529-556.	5.6	332
38	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care and Research, 2020, 72, 461-488.	3.4	122
39	Sex Differences in Systemic Lupus Erythematosus. Mayo Clinic Proceedings, 2020, 95, 384-394.	3.0	83
40	Gerald Weissmann: Inflammation in rheumatic disease. Annals of the Rheumatic Diseases, 2020, 79, 435-436.	0.9	1
41	A review of fetal and neonatal consequences of maternal systemic lupus erythematosus. Prenatal Diagnosis, 2020, 40, 1066-1076.	2.3	22
42	Integrated urine proteomics and renal single-cell genomics identify an IFN- β response gradient in lupus nephritis. JCI Insight, 2020, 5, .	5.0	57
43	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Self-Administered Questionnaires. Clinical Pharmacology and Therapeutics, 2019, 106, 374-382.	4.7	30
44	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. Arthritis Care and Research, 2019, 71, 949-960.	3.4	38
45	Antinuclear Antibody-“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
46	Systemic Lupus Erythematosus and Increased Prevalence of Atherosclerotic Cardiovascular Disease in Hospitalized Patients. Mayo Clinic Proceedings, 2019, 94, 1436-1443.	3.0	28
47	Single-cell RNA sequencing for the study of lupus nephritis. Lupus Science and Medicine, 2019, 6, e000329.	2.7	6
48	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. Lupus Science and Medicine, 2019, 6, e000344.	2.7	22
49	The immune cell landscape in kidneys of patients with lupus nephritis. Nature Immunology, 2019, 20, 902-914.	14.5	501
50	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nature Immunology, 2019, 20, 915-927.	14.5	275
51	Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. Journal of Experimental Medicine, 2019, 216, 1154-1169.	8.5	56
52	Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Annals of the Rheumatic Diseases, 2019, 78, 947-956.	0.9	274
53	273-...Safety of research cores obtained from clinically indicated biopsies in the accelerating medicines partnership network. , 2019, , .		0
54	300-...Insights from single-cell RNA sequencing of skin and kidney in lupus nephritis. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	SLE: reconciling heterogeneity. <i>Lupus Science and Medicine</i> , 2019, 6, e000280.	2.7	23
56	Neonatal Lupus. , 2019, , 486-498.		1
57	Human low-affinity IgG receptor FcγRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 532-537.	3.8	20
58	Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block. <i>Journal of Immunology</i> , 2019, 202, 48-55.	0.8	39
59	PD-1hiCXCR5+ T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019, 4, .	5.0	171
60	Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 549-555.	0.9	124
61	Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 230-235.	3.4	41
62	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	4.7	48
63	Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 13-17.	2.1	8
64	GG-02...Apolipoprotein L1 risk variants associate with increased SLE damage independent of inflammation in Ghanaian SLE patients. , 2018, , .		0
65	AI-06...Lupus nephritis is linked to dysbiosis, increased gut leakiness and immunity to an intestinal commensal lachnospiraceae species. , 2018, , .		0
66	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1742-1749.	0.9	40
67	Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis. <i>Lupus Science and Medicine</i> , 2018, 5, e000271.	2.7	8
68	Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring. <i>Arthritis and Rheumatology</i> , 2018, 70, 1801-1806.	5.6	34
69	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 36.	3.5	20
70	The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. <i>Rheumatology</i> , 2018, 57, v9-v17.	1.9	47
71	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018, 5, e000263.	2.7	18
72	Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus. <i>Journal of Autoimmunity</i> , 2017, 79, 99-104.	6.5	13

#	ARTICLE	IF	CITATIONS
73	Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1 β Pathway in Systemic Lupus Erythematosus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 707-716.	2.4	77
74	Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Current Opinion in Rheumatology, 2017, 29, 467-472.	4.3	39
75	Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H631-H640.	3.2	15
76	Brief Report: Association of Natural Killer Cell Ligand Polymorphism HLA-C Asn80Lys With the Development of Anti-SSA/Ro-Associated Congenital Heart Block. Arthritis and Rheumatology, 2017, 69, 2170-2174.	5.6	11
77	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis and Rheumatology, 2017, 69, 2006-2017.	5.6	126
78	Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmunity Reviews, 2017, 16, 980-983.	5.8	25
79	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight, 2017, 2, .	5.0	164
80	Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. PLoS ONE, 2017, 12, e0182483.	2.5	21
81	No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. Clinical and Experimental Rheumatology, 2017, 35, 857-859.	0.8	4
82	Neonatal Lupus. , 2016, , 451-461.		1
83	Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis and Rheumatology, 2016, 68, 1964-1969.	5.6	33
84	Endosomal Toll-like receptors in clinically overt and silent autoimmunity. Immunological Reviews, 2016, 269, 76-84.	6.0	35
85	Modulation of natural IgM autoantibodies to oxidative stress-related neo-epitopes on apoptotic cells in newborns of mothers with anti-Ro autoimmunity. Journal of Autoimmunity, 2016, 73, 30-41.	6.5	10
86	Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Science and Medicine, 2016, 3, e000165.	2.7	18
87	Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell, 2016, 166, 88-101.	28.9	340
88	Neonatal Lupus Erythematosus. , 2016, , 336-350.e8.		2
89	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Science and Medicine, 2016, 3, e000131.	2.7	118
90	Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Annals of the Rheumatic Diseases, 2016, 75, 1161-1165.	0.9	81

#	ARTICLE	IF	CITATIONS
91	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	3.0	118
92	Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block. Journal of Autoimmunity, 2016, 67, 36-45.	6.5	19
93	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. American Journal of Obstetrics and Gynecology, 2016, 214, 108.e1-108.e14.	1.3	122
94	Blockade of Interferon- γ Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2713-2722.	5.6	60
95	A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Science and Medicine, 2015, 2, e000087.	2.7	12
96	Predictors of Pregnancy Outcomes in Patients With Lupus. Annals of Internal Medicine, 2015, 163, 153-163.	3.9	393
97	The clinical spectrum of autoimmune congenital heart block. Nature Reviews Rheumatology, 2015, 11, 301-312.	8.0	209
98	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. Journal of Rheumatology, 2015, 42, 2288-2295.	2.0	79
99	Reactivity to the p305 Epitope of the β -Type Calcium Channel and Autoimmune-Associated Congenital Heart Block. Journal of the American Heart Association, 2015, 4, .	3.7	7
100	Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus. Journal of the American College of Cardiology, 2015, 66, 930-939.	2.8	32
101	Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue. Lupus Science and Medicine, 2014, 1, e000033.	2.7	0
102	Prevention and Treatment In Utero of Autoimmune-Associated Congenital Heart Block. Cardiology in Review, 2014, 22, 263-267.	1.4	90
103	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Science and Medicine, 2014, 1, e000056.	2.7	65
104	Neonatal Lupus. , 2014, , 251-272.		3
105	A 2014 update on the management of patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2014, 44, e1-e2.	3.4	17
106	Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus. Clinical Immunology, 2014, 153, 1-7.	3.2	36
107	Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials." by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45. Autoimmunity Reviews. 2014. 13. 70-72.	5.8	7
108	Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. Experimental and Molecular Pathology, 2013, 95, 121-123.	2.1	9

#	ARTICLE	IF	CITATIONS
109	Ro60 Requires Y3 RNA for Cell Surface Exposure and Inflammation Associated with Cardiac Manifestations of Neonatal Lupus. <i>Journal of Immunology</i> , 2013, 191, 110-116.	0.8	47
110	A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies. <i>Rheumatology</i> , 2013, 52, 1448-1453.	1.9	11
111	Complement Receptor 3 Influences Toll-like Receptor 7/8-Dependent Inflammation. <i>Journal of Biological Chemistry</i> , 2013, 288, 9077-9083.	3.4	48
112	Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. <i>Rheumatology</i> , 2012, 51, 1086-1092.	1.9	96
113	Neonatal lupus. <i>Current Opinion in Rheumatology</i> , 2012, 24, 466-472.	4.3	44
114	Cardiac Manifestations of Neonatal Lupus. <i>Cardiology in Review</i> , 2012, 20, 72-76.	1.4	61
115	Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis. <i>Journal of Rheumatology</i> , 2012, 39, 510-515.	2.0	6
116	Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus. <i>Circulation</i> , 2012, 126, 76-82.	1.6	363
117	Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. <i>Arthritis Care and Research</i> , 2012, 64, 1373-1381.	3.4	39
118	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
119	Neonatal Lupus. , 2011, , 541-571.		11
120	Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. <i>Arthritis and Rheumatism</i> , 2011, 63, 2783-2789.	6.7	30
121	Maternal and Fetal Factors Associated With Mortality and Morbidity in a Multi-Racial/Ethnic Registry of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus. <i>Circulation</i> , 2011, 124, 1927-1935.	1.6	257
122	A Novel Role of Endothelin-1 in Linking Toll-like Receptor 7-mediated Inflammation to Fibrosis in Congenital Heart Block. <i>Journal of Biological Chemistry</i> , 2011, 286, 30444-30454.	3.4	55
123	Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 1138-1146.	6.7	211
124	Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. <i>Arthritis and Rheumatism</i> , 2010, 62, 1153-1157.	6.7	119
125	Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. <i>Arthritis and Rheumatism</i> , 2010, 62, 3415-3424.	6.7	84
126	Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1827-1830.	0.9	192

#	ARTICLE	IF	CITATIONS
127	Ro60-Associated Single-Stranded RNA Links Inflammation with Fetal Cardiac Fibrosis via Ligation of TLRs: A Novel Pathway to Autoimmune-Associated Heart Block. Journal of Immunology, 2010, 184, 2148-2155.	0.8	89
128	Congenital heart block: Identification of autoantibody binding site on the extracellular loop (domain) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 8.5 59		
129	Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 89-95.	2.0	51
130	Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nature Reviews Rheumatology, 2009, 5, 139-148.	8.0	73
131	Prospective Evaluation of Fetuses With Autoimmune-Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. American Journal of Cardiology, 2009, 103, 1102-1106.	1.6	171
132	Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis and Rheumatism, 2009, 60, 3091-3097.	6.7	135
133	Updates on lupus and pregnancy. Bulletin of the NYU Hospital for Joint Diseases, 2009, 67, 271-5.	0.7	14
134	Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block. Circulation, 2008, 117, 485-493.	1.6	282
135	Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology, 2008, 48, 513-519.	1.9	24
136	Neonatal Lupus Syndromes. Rheumatic Disease Clinics of North America, 2007, 33, 267-285.	1.9	84
137	Estrogens and lupus: Bubbling cauldron or another overrated Witches' Brew?. Arthritis and Rheumatism, 2007, 56, 1048-1050.	6.7	6
138	Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Current Rheumatology Reports, 2007, 9, 101-108.	4.7	80
139	The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 2006, 54, 3623-3632.	6.7	130
140	Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. Journal of Clinical Investigation, 2006, 116, 2413-22.	8.2	140
141	The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial. Annals of Internal Medicine, 2005, 142, 953.	3.9	539
142	Autoantibody-associated congenital heart block: TGF β 2 and the road to scar. Autoimmunity Reviews, 2005, 4, 1-7.	5.8	37
143	Identifying an early marker for congenital heart block: When is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis and Rheumatism, 2005, 52, 1341-1342.	6.7	10
144	Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis and Rheumatism, 2005, 52, 3079-3086.	6.7	64

#	ARTICLE	IF	CITATIONS
145	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. New England Journal of Medicine, 2005, 353, 2550-2558.	27.0	962
146	Neonatal Lupus: Basic Research and Clinical Perspectives. Rheumatic Disease Clinics of North America, 2005, 31, 299-313.	1.9	84
147	Autoantibodies against the serotonergic 5-HT ₄ receptor and congenital heart block: A reassessment. Journal of Autoimmunity, 2005, 25, 72-76.	6.5	32
148	The Fetal Doppler Mechanical PR Interval: A Validation Study. Fetal Diagnosis and Therapy, 2004, 19, 31-34.	1.4	71
149	Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis and Rheumatism, 2004, 50, 173-182.	6.7	135
150	Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor γ : Implications for pathogenesis. Arthritis and Rheumatism, 2004, 50, 2598-2603.	6.7	46
151	Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. Journal of Rheumatology, 2004, 31, 2480-7.	2.0	90
152	Autoantibody-associated congenital heart block: The clinical perspective. Current Rheumatology Reports, 2003, 5, 374-378.	4.7	5
153	Maternal autoantibodies and congenital heart block: mediators, markers, and therapeutic approach. Seminars in Arthritis and Rheumatism, 2003, 33, 140-154.	3.4	70
154	From antibody insult to fibrosis in neonatal lupus - the heart of the matter. Arthritis Research, 2003, 5, 266.	2.0	16
155	Letter to the Editor. Lupus, 2003, 12, 646-647.	1.6	64
156	Cytokine Polymorphisms and Histologic Expression in Autopsy Studies: Contribution of TNF- α and TGF- β 1 to the Pathogenesis of Autoimmune-Associated Congenital Heart Block. Journal of Immunology, 2003, 171, 3253-3261.	0.8	92
157	Neonatal Lupus: Review of Proposed Pathogenesis and Clinical Data from the US-based Research Registry for Neonatal Lupus. Autoimmunity, 2003, 36, 41-50.	2.6	74
158	Clearance of apoptotic cells: TGF- β 2 in the balance between inflammation and fibrosis. Journal of Leukocyte Biology, 2003, 74, 959-960.	3.3	35
159	Neonatal lupus syndromes. Current Opinion in Rheumatology, 2003, 15, 535-541.	4.3	76
160	Neonatal Lupus Syndromes: Clinical Features. Handbook of Systemic Autoimmune Diseases, 2003, , 163-188.	0.1	1
161	Transdifferentiation of Cardiac Fibroblasts, a Fetal Factor in Anti-SSA/Ro-SSB/La Antibody-Mediated Congenital Heart Block. Journal of Immunology, 2002, 169, 2156-2163.	0.8	94
162	Hepatobiliary Disease in Neonatal Lupus: Prevalence and Clinical Characteristics in Cases Enrolled in a National Registry. Pediatrics, 2002, 109, e11-e11.	2.1	132

#	ARTICLE	IF	CITATIONS
163	Cardiac 5-HT ₄ Serotonergic Receptors, 52kD SSA/Ro and Autoimmune-Associated Congenital Heart Block. <i>Journal of Autoimmunity</i> , 2002, 19, 79-86.	6.5	29
164	Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system. <i>Arthritis and Rheumatism</i> , 2002, 46, 202-208.	6.7	69
165	The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: Implications in neonatal lupus. <i>Arthritis and Rheumatism</i> , 2002, 46, 269-271.	6.7	26
166	Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. <i>Arthritis and Rheumatism</i> , 2002, 46, 1572-1579.	6.7	83
167	Long-term followup of children with neonatal lupus and their unaffected siblings. <i>Arthritis and Rheumatism</i> , 2002, 46, 2377-2383.	6.7	149
168	Congenital heart block in neonatal lupus: The pediatric cardiologist's perspective. <i>Indian Journal of Pediatrics</i> , 2002, 69, 517-522.	0.8	33
169	Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system. , 2002, 46, 202.		2
170	Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. <i>Journal of the American College of Cardiology</i> , 2001, 37, 238-242.	2.8	360
171	Circulating activated endothelial cells in systemic lupus erythematosus: Further evidence for diffuse vasculopathy. <i>Arthritis and Rheumatism</i> , 2001, 44, 1203-1208.	6.7	111
172	High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. <i>Arthritis and Rheumatism</i> , 2001, 44, 1466-1467.	6.7	187
173	Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 550.	6.7	162
174	Pulsed Doppler echocardiographic assessment of the fetal PR interval. <i>American Journal of Cardiology</i> , 2000, 86, 236-239.	1.6	148
175	Clinical trials in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000, 2, 11-12.	4.7	2
176	Anti-SSA/Ro and Anti-SSB/La Autoantibodies Bind the Surface of Apoptotic Fetal Cardiocytes and Promote Secretion of TNF- α by Macrophages. <i>Journal of Immunology</i> , 2000, 165, 5345-5351.	0.8	181
177	Cutaneous manifestations of neonatal lupus without heart block: Characteristics of mothers and children enrolled in a national registry. <i>Journal of Pediatrics</i> , 2000, 137, 674-680.	1.8	231
178	Electrocardiographic Abnormalities in a Murine Model Injected With IgG From Mothers of Children With Congenital Heart Block. <i>Circulation</i> , 1999, 99, 1914-1918.	1.6	84
179	Assessing disease activity in SLE patients during pregnancy. <i>Lupus</i> , 1999, 8, 677-684.	1.6	166
180	Classification and definition of major flares in SLE clinical trials. <i>Lupus</i> , 1999, 8, 685-691.	1.6	220

#	ARTICLE	IF	CITATIONS
181	Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: Retrospective review of the research registry for neonatal lupus. <i>Arthritis and Rheumatism</i> , 1999, 42, 2335-2345.	6.7	291
182	mRNA and Protein Expression of SSA/Ro and SSB/La in Human Fetal Cardiac Myocytes Cultured Using a Novel Application of the Langendorff Procedure. <i>Pediatric Research</i> , 1999, 45, 260-269.	2.3	18
183	Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. <i>Arthritis and Rheumatism</i> , 1998, 41, 1026-1039.	6.7	86
184	Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1658-1666.	2.8	700
185	The effects of pregnancy on autoimmune diseases. <i>Journal of Leukocyte Biology</i> , 1998, 63, 281-287.	3.3	120
186	Serum and Immunoglobulin G from the Mother of a Child with Congenital Heart Block Induce Conduction Abnormalities and Inhibit L-Type Calcium Channels in a Rat Heart Model. <i>Pediatric Research</i> , 1998, 44, 11-19.	2.3	88
187	Differential phosphorylation of the β 2 integrin CD11b/CD18 in the plasma and specific granule membranes of neutrophils. <i>Journal of Leukocyte Biology</i> , 1997, 61, 313-321.	3.3	20
188	NEONATAL LUPUS SYNDROMES. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 31-54.	1.9	85
189	The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex. <i>Arthritis and Rheumatism</i> , 1997, 40, 936-944.	6.7	69
190	Connective tissue disease registries. <i>Arthritis and Rheumatism</i> , 1997, 40, 1556-1559.	6.7	20
191	Arrhythmogenicity of IgG and Anti-52-kD SSA/Ro Affinity-Purified Antibodies From Mothers of Children With Congenital Heart Block. <i>Circulation Research</i> , 1997, 80, 354-362.	4.5	144
192	The Effects of Pregnancy on Autoimmune Diseases. <i>Clinical Immunology and Immunopathology</i> , 1996, 78, 99-104.	2.0	37
193	Cloning and expression of mouse 60 kDa ribonucleoprotein SS-A/Ro. <i>Molecular Biology Reports</i> , 1996, 23, 205-210.	2.3	31
194	Heterogeneity in the expression of ro and la antigens in human skin. <i>Arthritis and Rheumatism</i> , 1995, 38, 1271-1276.	6.7	17
195	Successful in utero therapy of fetal heart block. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 1384-1390.	1.3	133
196	Up-Regulation of Endothelial Cell Adhesion Molecules Characterizes Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1994, 37, 376-383.	6.7	171
197	Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SSA/Ro and anti-SSB/La antibodies. <i>Arthritis and Rheumatism</i> , 1993, 36, 1263-1273.	6.7	208
198	Review: Congenital Complete Heart Block. <i>Lupus</i> , 1993, 2, 291-295.	1.6	28

#	ARTICLE	IF	CITATIONS
199	Activation of the Complement Pathway: Comparison of Normal Pregnancy, Preeclampsia, and Systemic Lupus Erythematosus During Pregnancy. American Journal of Reproductive Immunology, 1992, 28, 183-187.	1.2	53
200	Activation of the Alternative Complement Pathway Accompanies Disease Flares in Systemic Lupus Erythematosus During Pregnancy. Arthritis and Rheumatism, 1992, 35, 55-61.	6.7	90
201	Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis and Rheumatism, 1992, 35, 1028-1037.	6.7	104
202	Onset and Regulation of Anti-Lamin b Autoantibody Production is Independent of the Level of Polyclonal Activation. Autoimmunity, 1991, 8, 297-305.	2.6	11
203	Serum activity that confers acid lability to $\hat{\imath}$ -interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating $\hat{\imath}$ -interferon. Arthritis and Rheumatism, 1990, 33, 563-568.	6.7	20
204	Congenital complete heart block. Arthritis and Rheumatism, 1990, 33, 609-614.	6.7	108
205	Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis. Journal of Immunological Methods, 1990, 129, 207-210.	1.4	82
206	Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis and Rheumatism, 1988, 31, 632-641.	6.7	115
207	Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus. Arthritis and Rheumatism, 1987, 30, 44-49.	6.7	154
208	Female hormones reduce neutrophil responsiveness in vitro. Arthritis and Rheumatism, 1984, 27, 623-630.	6.7	108
209	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. Arthritis Care and Research, 0, , .	3.4	2
210	To Be or Not to Be Treated: That Is the Question in Managing a Fetus With Cardiac Injury Exposed to Anti-SSA/Ro. Journal of the American Heart Association, 0, , .	3.7	1